The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia

被引:20
|
作者
Buccisano, Francesco [1 ]
Hourigan, Christopher S. [2 ]
Walter, Roland B. [3 ,4 ,5 ]
机构
[1] Univ Tor Vergata, Dept Biomed & Prevent, Hematol, Via Montpellier 1, I-00133 Rome, Italy
[2] NHLBI, Myeloid Malignancies Sect, Hematol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA
[4] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA
[5] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Acute myeloid leukemia; Flow cytometry; Minimal residual disease; Next-generation sequencing; Polymerase chain reaction; Prognostication; HEMATOPOIETIC-CELL TRANSPLANTATION; MULTIPARAMETER FLOW-CYTOMETRY; INTERNATIONAL EXPERT PANEL; ACUTE MYELOGENOUS LEUKEMIA; CLONAL HEMATOPOIESIS; COMPLETE REMISSION; CLINICAL-SIGNIFICANCE; RELAPSE RISK; MYELODYSPLASTIC SYNDROMES; THERAPEUTIC IMPLICATIONS;
D O I
10.1007/s11899-017-0420-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this review was to evaluate recent literature on detection methodologies for, and prognostic significance of, measurable ("minimal") residual disease (MRD) in acute myeloid leukemia (AML). There is no "one-fits-all" approach to MRD testing in AML. Most exploited to date are methods relying on immunophenotypic aberrancies (identified via multiparameter flow cytometry) or genetic abnormalities (identified via PCR-based assays). Current methods have important shortcomings, including the lack of assay platform standardization/harmonization across laboratories. In parallel to refinements of existing technologies and data analysis/interpretation, new methodologies (e.g., next-generation sequencing-based assays) are emerging that eventually may complement or replace existing ones. This dynamic evolution of MRD testing has complicated comparisons between individual studies. Nonetheless, an ever-growing body of data demonstrates that a positive MRD test at various time points throughout chemotherapy and hematopoietic cell transplantation identifies patients at particularly high risks of disease recurrence and short survival even after adjustment for other risk factors.
引用
收藏
页码:547 / 556
页数:10
相关论文
共 50 条
  • [31] THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Samra, A.
    Kamel, M.
    El Sharkawy, M.
    El Fatah, M. Abd
    Ghaleb, M.
    Kamel, M.
    Abdelhamid, Th.
    Elemary, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 564 - 564
  • [32] Minimal Residual Disease Quantitation in Acute Myeloid Leukemia
    Shook, David
    Coustan-Smith, Elaine
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Campana, Dario
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S281 - S285
  • [33] Molecular Minimal Residual Disease in Acute Myeloid Leukemia
    Jongen-Lavrencic, M.
    Grob, T.
    Hanekamp, D.
    Kavelaars, F. G.
    al Hinai, A.
    Zeilemaker, A.
    Erpelinck-Verschueren, C. A. J.
    Gradowska, P. L.
    Meijer, R.
    Cloos, J.
    Biemond, B. J.
    Graux, C.
    Kooy, M. van Marwijk
    Manz, M. G.
    Pabst, T.
    Passweg, J. R.
    Havelange, V.
    Ossenkoppele, G. J.
    Sanders, M. A.
    Schuurhuis, G. J.
    Lowenberg, B.
    Valk, P. J. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1189 - 1199
  • [34] Molecular Minimal Residual Disease in Acute Myeloid Leukemia
    Mauvieux, Laurent
    Miguet, Laurent
    Fornecker, Luc
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25): : 2442 - +
  • [35] Monitoring of minimal residual disease in acute myeloid leukemia
    Kern, W
    Schoch, C
    Haferlach, T
    Schnittger, S
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (02) : 283 - 309
  • [36] MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA PATIENTS
    Van der Velden, Vincent
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (06) : 416 - 416
  • [37] Monitoring of minimal residual disease in acute myeloid leukemia
    Kern, Wolfgang
    Haferlach, Claudia
    Haferlach, Torsten
    Schnittger, Susanne
    CANCER, 2008, 112 (01) : 4 - 16
  • [38] Introducing minimal residual disease in acute myeloid leukemia
    Ofran, Yishai
    Rowe, Jacob M.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (02) : 139 - 145
  • [39] Minimal residual disease in patients with acute myeloid leukemia
    Galtseva, IV
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1998, 43 (01): : 10 - 11
  • [40] Assessment of minimal residual disease in acute myeloid leukemia
    Grimwade, David
    Vyas, Paresh
    Freeman, Sylvie
    CURRENT OPINION IN ONCOLOGY, 2010, 22 (06) : 656 - 663